Travere Therapeutics (TVTX) Tops Q4 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
February 23, 2023 4:01 PM ESTRecently received U.S. FDA accelerated approval of FILSPARI (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy (IgAN)
European Medicines Agency (EMA) review decision for potential conditional approval of sparsentan in IgAN anticipated in second half of 2023
Pivotal DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS)Â on track to report topline data from confirmatory two-year endpoints in second quarter of 2023
Net product sales of $52 million for the fourth quarter of 2022; $201 million for the full year... More
